Recent Updates
Recently added Catalysts
KLRS Positive Sentiment

Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference

Key Takeaway: Kalaris Therapeutics announced that its management team will participate in a Fireside Chat at the Morgan Stanley 24th Annual Global Healthcare Conference. The session is scheduled for Tuesday, September 15, 2026, in New York. Chief Executive Officer Andrew Oxtoby and Chief Medical Officer Matthew Feinsod will lead the discussion. Kalaris is currently developing TH103 for neovascular Age-related Macular Degeneration.
Price reaction · baseline $4.03 (2026-08-28 close) · hit pre-market · clean, no other KLRS news in the window
day 0 close
+0.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Kalaris is actively participating in a significant healthcare conference.
  • The company focuses on prevalent retinal diseases, indicating a targeted approach.
  • Management's presence at the conference suggests confidence in their pipeline.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+359%
120-day peak, hindsight
Typical move
9.9%
average across 3 past catalysts
Cash runway
~23 mo
Low dilution risk
Lead asset
Posoleucel
Phase 3 · Adenovirus Infection

Full Press Release Details

BERKELEY HEIGHTS, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will participate in a Fireside Chat at the upcoming Morgan Stanley 24th Annual Global Healthcare Conference. Kalaris is currently developing TH103, a dual-action anti-VEGF therapeutic, in a Phase 1b/2 multiple ascending dose study for neovascular Age-related Macular Degeneration (nAMD).
Details:
• Type : Fireside chat
• Speakers : Andrew Oxtoby, Chief Executive Officer & Matthew Feinsod, Chief Medical Officer
• Date : Tuesday, September 15, 2026
• Time : 4:05 – 4:40pm EDT
• Location : New York, NY
Kalaris management will be available for one-on-one meetings during the conference. Interested parties should contact their conference representative to arrange a meeting.
About TH103 TH103 is an investigational dual-targeting biologic with the potential to be best-in class for neovascular and exudative retinal diseases. TH103 was engineered by VEGF scientific discoverer Dr. Napoleone Ferrara to achieve extended intraocular retention with enhanced VEGF inhibition through optimized binding to VEGF receptor 1 ligands and concurrent heparan sulfate proteoglycan (HSPG) anchoring. It is a fully humanized, recombinant fusion protein designed for intravitreal delivery, with potential applications as a treatment for exudative and/or neovascular retinal diseases, such as neovascular Age-related Macular Degeneration (nAMD), diabetic eye disease and retinal vein occlusion. TH103 is currently being investigated in a Phase 1b/2 clinical trial in patients with nAMD.
About Kalaris Kalaris Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases. Founded by renowned scientist Dr. Napoleone Ferrara, whose pioneering research led to the development of anti-VEGF therapy, the company is committed to advancing novel therapeutic approaches for patients with sight-threatening retinal conditions with major unmet medical needs. For more information, visit www.kalaristx.com .

Frequently Asked Questions

What is Kalaris Therapeutics focused on?

Kalaris Therapeutics is dedicated to developing treatments for prevalent retinal diseases.

When is the Morgan Stanley conference?

The article does not specify the exact date of the Morgan Stanley conference.

Who will represent Kalaris at the conference?

Management from Kalaris Therapeutics will represent the company at the conference.

Last updated: Aug 31, 2026